Study of AVZO-021 in Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT05867251. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors
Study identification
- NCT ID
- NCT05867251
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Avenzo Therapeutics, Inc.
- Industry
- Enrollment
- 430 participants
Conditions and interventions
Conditions
Interventions
- AVZO-021 Drug
- Abemaciclib Drug
- Carboplatin Drug
- Fulvestrant Drug
- Letrozole Drug
- Palbociclib Drug
- Ribociclib Drug
- Sacituzumab Govitecan-hziy Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 29, 2023
- Primary completion
- Jan 30, 2028
- Completion
- Jan 30, 2030
- Last update posted
- Nov 18, 2025
2023 – 2030
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Yale Cancer Center | New Haven | Connecticut | 06520 | Recruiting |
| Florida Cancer Specialists | Sarasota | Florida | 34232 | Recruiting |
| Moffitt Cancer Center | Tampa | Florida | 33612 | Recruiting |
| Perlmutter Cancer Center at NYU Langone Hospital - Long Island | Mineola | New York | 11501 | Recruiting |
| NYU Langone Medical Center (Tisch Hospital) | New York | New York | 10016 | Recruiting |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | Recruiting |
| Oklahoma University | Oklahoma City | Oklahoma | 73117 | Recruiting |
| Providence Cancer Institute | Portland | Oregon | 97213 | Recruiting |
| Sidney Kimmel Cancer Center (SKCC) at Jefferson Health | Philadelphia | Pennsylvania | 19107 | Recruiting |
| Texas Oncology - DFW | Dallas | Texas | 75246 | Recruiting |
| NEXT Virginia | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05867251, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 18, 2025 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05867251 live on ClinicalTrials.gov.